SCHEMBL15549219

SCHEMBL15549219

CSc1ncc(C(=O)C2CC2)c(Cl)n1

nearest known ligand 0.45

Predicted protein targets (top 13)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 4/20 0.45
MEN1 O00255 3/20 0.45
AHR P35869 1/20 0.42
MAPT P10636 2/20 0.39
HPGD P15428 1/20 0.39
LMNA P02545 2/20 0.39
KDM4E B2RXH2 1/20 0.39
RXFP1 Q9HBX9 1/20 0.38
THRB P10828 1/20 0.38
PDE4B Q07343 2/20 0.37
POLB P06746 1/20 0.37
SMN1; SMN2 Q16637 1/20 0.36
ALDH1A1 P00352 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2226205 0.79 MEN1 (0.60) KMT2AMEN1AHRMAPTHPGD
SCHEMBL17773665 0.79 MEN1 (0.51) KMT2AMEN1AHRMAPTHPGD
SCHEMBL5656811 0.79 MEN1 (0.51) KMT2AMEN1AHRMAPTHPGD
SCHEMBL29172704 0.78 MEN1 (0.42) KMT2AMEN1AHRMAPTHPGD
SCHEMBL15598486 0.78 MEN1 (0.47) KMT2AMEN1AHRMAPTHPGD
SCHEMBL14587559 0.78 MEN1 (0.50) KMT2AMEN1AHRMAPTHPGD
Hydrochloric Acid SCHEMBL10559938 0.78 MEN1 (0.58) KMT2AMEN1AHRMAPTHPGD
SCHEMBL14492513 0.76 MEN1 (0.53) KMT2AMEN1AHRMAPTHPGD
SCHEMBL5211841 0.75 MEN1 (0.47) KMT2AMEN1AHRMAPTHPGD
SCHEMBL19630932 0.75 MEN1 (0.47) KMT2AMEN1AHRMAPTHPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20150307520-A1 NOVEL HETEROARYL AND HETEROCYCLE COMPOUNDS, COMPOSITIONS AND METHODS THEREOF HUTCHISON MEDIPHARMA LTD (CN) 2015-10-29 US disclosed
US-20150307520-A1 NOVEL HETEROARYL AND HETEROCYCLE COMPOUNDS, COMPOSITIONS AND METHODS THEREOF HUTCHISON MEDIPHARMA LTD (CN) 2015-10-29 US disclosed
US-20150307520-A1 NOVEL HETEROARYL AND HETEROCYCLE COMPOUNDS, COMPOSITIONS AND METHODS THEREOF HUTCHISON MEDIPHARMA LTD (CN) 2015-10-29 US disclosed
US-20150291593-A1 NOVEL HETEROARYL AND HETEROCYCLE COMPOUNDS, COMPOSITIONS AND METHODS HUTCHISON MEDIPHARMA LTD (CN) 2015-10-15 US disclosed
US-20150291593-A1 NOVEL HETEROARYL AND HETEROCYCLE COMPOUNDS, COMPOSITIONS AND METHODS HUTCHISON MEDIPHARMA LTD (CN) 2015-10-15 US disclosed
US-20150291593-A1 NOVEL HETEROARYL AND HETEROCYCLE COMPOUNDS, COMPOSITIONS AND METHODS HUTCHISON MEDIPHARMA LTD (CN) 2015-10-15 US disclosed
EP-2877472-A1 NOVEL HETEROARYL AND HETEROCYCLE COMPOUNDS, COMPOSITION AND METHODS THEREOF Hutchison Medipharma Limited (CN) 2015-06-03 EP disclosed
WO-2014015675-A1 NOVEL HETEROARYL AND HETEROCYCLE COMPOUNDS, COMPOSITIONS AND METHODS HUTCHISON MEDIPHARMA LIMITED (CN) 2014-01-30 WO disclosed
WO-2014015830-A1 NOVEL HETEROARYL AND HETEROCYCLE COMPOUNDS, COMPOSITION AND METHODS THEREOF HUTCHISON MEDIPHARMA LIMITED (CN) 2014-01-30 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150307520-A1 NOVEL HETEROARYL AND HETEROCYCLE COMPOUNDS, COMPOSITIONS AND METHODS THEREOF PIK3C3, PIK3C2B, PIK3C2A KMT2A 2620/4885MEN1 1139/4885AHR 406/4885
US-20150291593-A1 NOVEL HETEROARYL AND HETEROCYCLE COMPOUNDS, COMPOSITIONS AND METHODS PIK3C2B, PIK3C3, PIK3C2A KMT2A 2912/4885MEN1 1364/4885AHR 333/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.